Aquestive Therapeutics, Inc.
AQST
$4.06
$0.041.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 1.62% | 28.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.62% | 28.03% | |||
| Cost of Revenue | 29.52% | -1.21% | |||
| Gross Profit | -13.52% | 52.54% | |||
| SG&A Expenses | 115.23% | 20.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 72.34% | 13.64% | |||
| Operating Income | -151.23% | -0.98% | |||
| Income Before Tax | -106.27% | -14.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -106.27% | -14.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -106.27% | -14.01% | |||
| EBIT | -151.23% | -0.98% | |||
| EBITDA | -152.94% | -1.00% | |||
| EPS Basic | -86.97% | -2.42% | |||
| Normalized Basic EPS | -87.06% | -2.46% | |||
| EPS Diluted | -86.97% | -2.42% | |||
| Normalized Diluted EPS | -87.06% | -2.46% | |||
| Average Basic Shares Outstanding | 10.29% | 11.33% | |||
| Average Diluted Shares Outstanding | 10.29% | 11.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||